Today: 20 May 2026
Browse Category

NASDAQ:SILX 20 May 2026

Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion reported Israeli clearance and a German filing for its SIL204 pancreatic cancer drug, keeping its Phase 2/3 trial on track for a second-quarter start. The company posted a first-quarter net loss of $2.7 million and held $2.4 million in cash at March 31. Shares closed at 26.9 cents Tuesday after a sharp drop last week. Management warned of “substantial doubt” about ongoing operations without new funding.
20 May 2026
··

Stock Market Today

  • U.S. Stock Market Closed on Memorial Day, Bond Market Early Closure Ahead
    May 20, 2026, 10:04 AM EDT. The U.S. stock market will be closed on Memorial Day, Monday, May 25, with the New York Stock Exchange and Nasdaq resuming normal hours on Tuesday. The U.S. bond market will close early at 2 p.m. EDT on Friday, May 22, and remain closed Monday. Over-the-counter trading will also be closed on Memorial Day. Internationally, the London Stock Exchange is closed for the Spring Bank holiday, while the Hong Kong and Tokyo exchanges remain open. This holiday pause impacts traders planning activity around the holiday weekend, as major U.S. financial markets observe federal and regional holidays.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Go toTop